ANO1 and prostate carcinoma: Down-regulation of ANO1 protein levels by RNAi in HNSCC, ESCC, prostate cancer, and breast cancer cells inhibits proliferation in vitro and in vivo by inhibiting activation of epidermal growth factor receptor and MAPK/AKT-signaling pathways and thus establishes ANO1 as an important survival factor in these cells (6, 7, 15).